Abstract：
BACKGROUND: Cancer immunotherapy has had an important role in oncologic therapeutics for patients with non-small cell lung cancer (NSCLC) using checkpoint inhibitors. We will explore the possible prognosis biomarker candidates such as: soluble OX40 (sOX40), OX40L (sOX40L), Glucocorticoid-induced tumor necrosis factor receptor family-related receptor (GITR), and their ligand (GITRL), 4-1BB or tumor necrosis factor receptor superfamily 9 (TNFRS9) and inducible T cell co-stimulator (ICOS) in peripheral blood of NSCLC patients.
METHODS: Fifty-eight patients were diagnosed with advanced NSCLC between January 2019 and March 2020.
RESULTS: High sOX40 and low s4-1BB levels in smokers compared non-smoker NSCLC patients. Lower sOX40L levels were found in the male than female (p < 0.05). High sOX40 and sGITRL in stage III compared to the stage IV (p < 0.05). With follow-up at 21.4 months, 44.1% and 91.1% were alive in the sGITRhigh and sGITRlow groups, respectively (p = 0.02), and 73.3% and 27.7% were alive in the sGITRLhigh and sGITRLlow groups, respectively (p = 0.02). At 22 months, 38.7% and 92.3% were alive in the sOX40Lhigh and sOX40Llow groups, respectively (p = 0.01).
CONCLUSIONS: sGITR, sGITRL, and sOX40L levels were potential prognostic biomarkers and could have an important role as new targets of immunotherapy in NSCLC patients. sGITR, sGITRL, sOX40L, and sOX40 levels were associated with smoking, sex, stage, and age in NSCLC.
METHODS: Fifty-eight patients were diagnosed with advanced NSCLC between January 2019 and March 2020.
RESULTS: High sOX40 and low s4-1BB levels in smokers compared non-smoker NSCLC patients. Lower sOX40L levels were found in the male than female (p < 0.05). High sOX40 and sGITRL in stage III compared to the stage IV (p < 0.05). With follow-up at 21.4 months, 44.1% and 91.1% were alive in the sGITRhigh and sGITRlow groups, respectively (p = 0.02), and 73.3% and 27.7% were alive in the sGITRLhigh and sGITRLlow groups, respectively (p = 0.02). At 22 months, 38.7% and 92.3% were alive in the sOX40Lhigh and sOX40Llow groups, respectively (p = 0.01).
CONCLUSIONS: sGITR, sGITRL, and sOX40L levels were potential prognostic biomarkers and could have an important role as new targets of immunotherapy in NSCLC patients. sGITR, sGITRL, sOX40L, and sOX40 levels were associated with smoking, sex, stage, and age in NSCLC.
摘要：
背景：癌症免疫疗法在使用检查点抑制剂治疗非小细胞肺癌（NSCLC）患者的肿瘤治疗中具有重要作用。我们将探索可能的预后生物标志物候选物，如：可溶性OX40（sOX40），OX40L(sOX40L),糖皮质激素诱导的肿瘤坏死因子受体家族相关受体(GITR),和它们的配体（GITRL），NSCLC患者外周血中的4-1BB或肿瘤坏死因子受体超家族9(TNFRS9)和诱导型T细胞共刺激因子(ICOS)。
方法：在2019年1月至2020年3月期间，58例患者被诊断为晚期NSCLC。
结果：与非吸烟者NSCLC患者相比，吸烟者的sOX40水平较高，s4-1BB水平较低。在男性中发现sOX40L水平低于女性(p<0.05)。与IV期相比,III期的sOX40和sGITRL较高(p<0.05)。随访21.4个月，在sGITRhigh和sGITRlow组中，有44.1％和91.1％存活，分别为（p=0.02），在sGITRLhigh和sGITRLlow组中，分别有73.3%和27.7%存活，分别（p=0.02）。22个月时,sOX40L高组和sOX40L低组的存活率为38.7%和92.3%,分别(p=0.01)。
结论：sGITR，sGITRL,sOX40L水平是潜在的预后生物标志物,可作为NSCLC患者免疫治疗的新靶点发挥重要作用。sGITR,sGITRL,sOX40L,sOX40水平与吸烟有关，性别,舞台,非小细胞肺癌的年龄。
方法：在2019年1月至2020年3月期间，58例患者被诊断为晚期NSCLC。
结果：与非吸烟者NSCLC患者相比，吸烟者的sOX40水平较高，s4-1BB水平较低。在男性中发现sOX40L水平低于女性(p<0.05)。与IV期相比,III期的sOX40和sGITRL较高(p<0.05)。随访21.4个月，在sGITRhigh和sGITRlow组中，有44.1％和91.1％存活，分别为（p=0.02），在sGITRLhigh和sGITRLlow组中，分别有73.3%和27.7%存活，分别（p=0.02）。22个月时,sOX40L高组和sOX40L低组的存活率为38.7%和92.3%,分别(p=0.01)。
结论：sGITR，sGITRL,sOX40L水平是潜在的预后生物标志物,可作为NSCLC患者免疫治疗的新靶点发挥重要作用。sGITR,sGITRL,sOX40L,sOX40水平与吸烟有关，性别,舞台,非小细胞肺癌的年龄。
